U.S. Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pain Medication, Hormone Therapy), By Drug Class (NSAIDs, Oral Contraceptive), By Route Of Administration (Oral), By Distribution Channel, And Segment Forecasts, 2025 - 2030

U.S. Endometriosis Treatment Market Trends

The U.S. endometriosis treatment market size was estimated at USD 656.23 million in 2024 and is projected to grow at a CAGR of 11.86% from 2025 to 2030. Endometriosis, a condition where tissue similar to the uterine lining develops outside the uterus, is becoming increasingly prevalent, driving the demand for effective treatments. In the United States, the condition impacts between 2% and 10% of women aged 25 to 40, according to Johns Hopkins Medicine. Endometriosis imposes substantial economic, social, and physical burdens on affected individuals, often diminishing their quality of life due to severe pain, depression, fatigue, anxiety, and infertility. For some, the intensity of symptoms can hinder their ability to attend school or maintain employment, further compounding the societal impact of the disease. These challenges emphasize the need for innovative and accessible treatment options.

Pharmaceutical companies are actively addressing this rising disease burden by introducing novel therapies aimed at improving patient outcomes. For instance, in August 2022, Pfizer Inc. and Myovant Sciences announced the U.S. FDA approval of MYFEMBREE, an oral treatment specifically designed to alleviate moderate to severe pain associated with endometriosis in premenopausal women. This development represents a significant step forward in addressing the unmet medical needs of patients suffering from this condition.

Awareness campaigns organized by public health departments and non-profit organizations also play a crucial role. The New York State Department of Health, for instance, observes March as Endometriosis Awareness Month annually, emphasizing the severe pain and infertility associated with the condition. Organizations like the Endometriosis Foundation contribute further by conducting research and providing platforms for individuals to share their experiences. These storytelling initiatives raise awareness of the challenges faced by people with endometriosis and encourage others to seek timely care and treatment.

The endometriosis treatment industry is poised for significant growth due to increasing funding for research and development. Governments, private organizations, and pharmaceutical companies are making substantial investments to address the rising prevalence of endometriosis and the need for effective treatments. Private sector funding is also accelerating the development of advanced treatments. For instance, in July 2019, Sunstone Life Science Ventures invested USD 5.59 million in Forendo Pharma, a Finnish clinical-stage drug development company specializing in women’s health. This funding supported clinical studies aimed at creating novel therapies for endometriosis. Similarly, in November 2022, AIMA Laboratories, a biotech company, secured USD 468.5 million to advance its blood-testing technology for at-home screening of endometriosis. Such investments are fostering the development of cutting-edge products and diagnostic platforms, thereby driving market growth

The availability of over-the-counter (OTC) and generic drugs poses a significant restraint on the growth of the endometriosis treatment market. Generic drugs are typically more affordable than branded medications, making them a preferred choice for cost-conscious patients. Many individuals opt for these lower-cost alternatives over prescription medications for endometriosis, particularly when managing mild symptoms. OTC non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, naproxen, and ibuprofen, are widely accessible and affordable. These medications are often chosen as first-line treatments due to their efficacy in alleviating pain and inflammation, offering a more economical option compared to hormonal therapies or surgical interventions.

Market Concentration & Characteristics

The U.S. endometriosis treatment industry demonstrates a high degree of innovation, driven by advancements in drug discovery, minimally invasive therapies, and hormonal treatment developments. Key areas of focus include next-generation GnRH (Gonadotropin-releasing Hormone) antagonists, personalized medicine approaches, and non-hormonal therapies targeting the inflammatory pathways associated with endometriosis. Continuous investment in R&D has resulted in improved symptom management and reduced recurrence rates, significantly enhancing patient quality of life and driving market growth.

The U.S. endometriosis treatment industry experiences a moderate to robust level of mergers and acquisitions (M&A), as pharmaceutical giants and specialty biotech firms focus on expanding their women’s health portfolios. Recent trends include the acquisition of innovative pipeline candidates targeting endometriosis pain and inflammation, as well as partnerships aimed at co-developing next-generation therapies. Strategic collaborations with medical device companies for adjunctive surgical solutions are also on the rise, enhancing the overall treatment landscape.

Regulatory frameworks heavily influence the U.S. endometriosis treatment industry. The FDA plays a pivotal role in approving novel therapies, particularly through expedited pathways like Breakthrough Therapy Designation and Fast Track for high-need indications. However, scrutiny over drug pricing and reimbursement challenges for specialty therapies pose hurdles for manufacturers. Legislative efforts, such as the Inflation Reduction Act, aim to enhance drug affordability, potentially affecting the pricing dynamics in the endometriosis segment.

The threat of product substitutes in the endometriosis treatment industry includes surgical interventions such as laparoscopy and hysterectomy, which are often used in conjunction with or as an alternative to pharmacological treatments. In addition, lifestyle interventions such as dietary management and physical therapy are gaining traction among patients seeking holistic care. Despite these alternatives, branded pharmaceuticals, particularly GnRH antagonists and hormonal therapies, maintain a strong market position due to their efficacy and established clinical outcomes.

Companies in the U.S. endometriosis treatment industry are strategically focusing on expanding their presence through improved patient outreach in both rural and urban areas. Telemedicine and digital health platforms are being leveraged to enhance diagnosis rates and ensure timely initiation of treatment. Collaborations with health systems and payers are critical for improving drug affordability and addressing the significant unmet need for accessible and effective endometriosis care.

Treatment Type Insights

Based on treatment type, the market is segmented into pain medication and hormone therapy. The hormone therapy segment led the market with the largest revenue share of 78.51% in 2024. The market for hormone therapy in endometriosis is poised for growth, driven by increasing awareness and diagnosis rates. Opportunities lie in developing therapies with fewer side effects, improved delivery systems, and personalized approaches. Advances in understanding endometriosis pathophysiology also present avenues for innovation, ensuring hormone therapy remains a cornerstone of treatment strategies.

The pain medication segment is expected to grow at a substantial CAGR over the forecast period. Pain medication plays a pivotal role in managing endometriosis, a chronic condition characterized by the growth of endometrial-like tissue outside the uterus, often causing debilitating pain and discomfort. For many patients, pain relief is the primary focus of treatment, especially when surgical or hormonal therapies are not suitable or as an adjunct to these methods. Effective pain management not only improves the quality of life for those affected but also allows them to maintain daily activities and overall well-being.

Drug Class Insights

Based on drug class, the market is segmented into NSAIDs, oral contraceptives, Gonadotropin-Releasing Hormone (GnRH), and others. The gonadotropin releasing hormone segment led the market with the largest revenue share of 51.33% in 2024. GnRH therapies in endometriosis treatment presents substantial opportunities. Increasing awareness, a growing prevalence of the condition, and the demand for minimally invasive solutions drive innovation. Advances in drug formulations, such as oral GnRH antagonists, and expanding indications in different patient demographics offer lucrative potential. As researchers explore combination therapies and novel delivery systems, GnRH-based treatments continue to hold a prominent position in this evolving therapeutic landscape.

The oral contraceptives segment play a crucial role in the management of endometriosis, offering a first-line treatment option for many patients. These medications work by regulating hormone levels, particularly estrogen and progesterone, to suppress ovulation and reduce the growth of endometrial tissue. This helps alleviate common symptoms like pelvic pain and irregular menstruation, improving the quality of life for individuals affected by the condition.

Route of Administration Insights

Based on route of administration, the market is segmented into oral, injectable, and others. The oral segment led the market with the largest revenue share of 49.14% in 2024. Oral medications play a pivotal role in the management of endometriosis, offering convenience, accessibility, and effective symptom control for patients. These treatments are particularly valuable for individuals seeking non-invasive options to manage chronic pain, inflammation, and menstrual irregularities caused by endometriosis. By targeting hormonal imbalances, oral drugs can significantly reduce the recurrence of lesions and enhance the quality of life for patients.

The injectable segment is expected to grow at the fastest CAGR of 12.41% over the forecast period. Primary uses of injections in endometriosis treatment involve the administration of GnRH agonists and antagonists. These medications are powerful tools for regulating hormonal fluctuations and managing endometriosis-related pain and inflammation. By delivering these drugs via injection, healthcare providers can ensure precise and controlled dosing, which is crucial in achieving the desired therapeutic effects. Furthermore, injectable progestins and other hormonal medications are used in endometriosis treatment. These injections offer a sustained and consistent release of hormones, which can be advantageous in managing symptoms.

Distribution Channel Insights

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment led the market with the largest revenue share of 60.99% in 2024. Retail pharmacies play a crucial role in the management and treatment of endometriosis by providing accessible points of care for patients. With the advent of new medications and treatments, retail pharmacies offer convenience, affordability, and widespread availability of essential drugs for managing chronic conditions like endometriosis. Notable pharmacy chains such as CVS Health, Walgreens Boots Alliance, Rite Aid, and Walmart Pharmacy ensure that patients can easily access prescribed medications, including hormonal therapies and pain relievers, which are key in treating endometriosis.

The hospital pharmacies segment is expected to grow at the fastest CAGR of 12.41% during the forecast period. Hospital pharmacies play a pivotal role in the management of endometriosis, ensuring timely access to specialized medications and tailored treatment regimens. Endometriosis often requires a multidisciplinary approach involving surgery, hormonal therapy, and pain management, all of which rely on the expertise and resources provided by hospital pharmacies.

Key U.S. Endometriosis Treatment Company Insights

Key market players are focusing on launching innovative products, and adopting various growth strategies, and technological advancements. Several market players are acquiring smaller players to strengthen their market positions. This strategy enables companies to increase their capabilities, expand product portfolios, and improve competencies. Some key players adopting this strategy are Teva Pharmaceutical Industries Ltd. and AbbVie, Inc.

Recent Developments

• In January 2024, Hera Biotech, Inc., a Texas-based biotechnology company specializing in tissue-based diagnostics for endometriosis, announced its acquisition of Scailyte AG, a Swiss firm known for its expertise in single-cell omics and AI-driven biomarker discovery. This strategic move aims to accelerate the development of non-invasive clinical diagnostic tests for endometriosis, enhancing early detection and personalized treatment options in the U.S. market.

• In February 2024, ObsEva SA and Theramex entered into a strategic licensing agreement to support the commercialization and expansion of Linzagolix across the global market. Linzagolix is being developed as a potential treatment for endometriosis-associated pain.

U.S. Endometriosis Treatment MarketReport Scope

U.S. Endometriosis Treatment Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the U.S. endometriosis treatment market report based on treatment type, drug class, route of administration, and distribution channel.

• Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Pain Medication

  • Hormone Therapy

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030

  • NSAIDs

  • Oral Contraceptive

  • Gonadotropin Releasing Hormone

  • Others

• Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Others